Bridge Biotherapeutics Holds Event to Celebrate 'Invention Day'

[Asia Economy Reporter Chunhee Lee] Bridge Biotherapeutics announced on the 19th that it held an internal commemorative event for employees at its headquarters in Seongnam-si, Gyeonggi Province, in celebration of the 57th 'Invention Day.'

The event held the previous day consisted of ▲ education to raise employee awareness about the importance of patent strategies in the pharmaceutical and bio industries and the current patent status related to the company's major development projects ▲ an internal briefing session on the employee invention reward system for organic innovative new drug research and development ▲ a commemorative event to reaffirm the commitment to new drug development considering patent strategies. The presentations were led by Director of Intellectual Property (IP) Byungkyu Kim and Executive Vice President of Strategy Jongjin Lim.

In the first session, Director Kim gave a presentation on the uniqueness of patents in the pharmaceutical and bio industries and Bridge Biotherapeutics' major patent strategies, stating, “Patents in the pharmaceutical and bio industries have the unique characteristic that the period of exclusive rights is relatively short compared to the long development period.” He added, “As our company emphasizes efficient development as a core value, efforts are needed to secure the maximum exclusivity period by ensuring patient safety while proceeding with timely new drug development.” He also mentioned the importance of comprehensive and organic cooperation among the strategy, research, business development, clinical development, and patent departments for innovative new drug development.

Additionally, focusing on the material patent case of the non-small cell lung cancer treatment candidate 'BBT-176,' which has recently been registered in multiple countries including the United States and South Korea, he shared the current major patent registration status and future strategies for the ulcerative colitis treatment candidate 'BBT-401' and the idiopathic pulmonary fibrosis treatment candidate 'BBT-877.'

Executive Vice President Lim stated that just as Bridge Biotherapeutics' major development candidates aim to be first-in-class or best-in-class drugs addressing global unmet needs, the patent strategy is also continuously being strengthened with the development of global blockbuster drugs in mind.

Finally, the employees attending the event reaffirmed the company's commitment to new drug development by lighting bulbs on a world map ceremony, symbolizing the strengthening of patent strategies.

Jungkyu Lee, CEO of Bridge Biotherapeutics, said, “Business development, including technology transfer (license-out) in the pharmaceutical and bio industries, ultimately involves transactions of patent licenses and financial compensation for the relevant projects, so conducting business based on efficient patent strategies is very important.” He added, “We will continue to do our best to further solidify patent strategies related to major research and development pipelines and strengthen our competitiveness in the global market.”